Navigation Links
Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody
Date:5/5/2010

Pharma, Merck Serono, Boehringer Ingelheim, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com

Safe Harbor Statement

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the operation of the global collaboration with Boehringer Ingelheim, the efficacy, safety and intended utilization of our product candidates, including the BiTE antibody that is the subject of the agreement with Boehringer Ingelheim, the mode of action of BiTE antibodies, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and the future payment of milestone and royalty payments by Boehringer Ingelheim. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Ingenuity Systems Announces Multi-Year Agreement With Boehringer Ingelheim
2. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
3. Boehringer Ingelheim and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts
4. More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheims Flomax as First-Line Therapy
5. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
6. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
8. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
9. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
10. Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
11. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... York, NY (PRWEB) May 21, 2013 Bed ... And according to My Cleaning Products, many turn to chemical-based ... because of the health and environmental risks those solutions present, ... with Bed Bug Bully instead. , According to ... bed bugs as they used to be. It shared that ...
(Date:5/21/2013)... 2013 Inflamax scientists worked closely ... to design the study, which will provide critical ... models used in the study of allergy treatments, ... Challenge (NAC) models. Although both the models are ... date no direct comparison between the allergic responses ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... Scientists are using the engineering technology behind the ... models for the replacement of delicate and complex ... The researchers, combining engineering and plastic ... topological optimization to design an experimental 3-D structure ...
... IRVINE, Calif. , July 12 ... the development and commercialization of personalized DNA-based diagnostics ... completed license agreements with key Norwegian cancer researchers. ... promising genomic technologies with the intention of developing ...
... , July 12, 2010 Points to,Novel Pathway for Drug ... Abdominal Aortic Aneurysm, Heart Attack and,PAD , ... Scientists at deCODE genetics and academic ... and North America today,report the discovery of a common ...
Cached Biology Technology:High-performance engineering used to design facial bone replacements 2High-performance engineering used to design facial bone replacements 3OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 2OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 3OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 4deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 2deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 4
(Date:5/21/2013)... have developed a new method for delivering molecules ... the cell surface. The technique could find applications ... fields. , Bulk electroporation a technique used ... in the cell membrane that are caused by ... increasingly popular method of cell transfection. (Cell transfection ...
(Date:5/21/2013)... the University of Illinois at Chicago College of Medicine will ... fat -- its main energy source -- and how changes ... a new $2 million, 4-year grant from the National Heart, ... how it uses fuel for energy. These changes may play ... are different in men and women, says E. Douglas Lewandowski, ...
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Do men's and women's hearts burn fuel differently? 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... a gas they also produce naturally as a hormone, the result ... and fading in the case of flowers all of which ... plants with products available in the market today, such as EthylBloc ... for fruits and vegetables, that contain a compound that blocks ...
... mechanism of action of genes has been hampered by the ... is true for even the most common class of cancer-associated ... events in cells by phosphorylating and modulating the activity of ... efforts that up to a quarter of kinases may play ...
... TAMPA, Fla., May 1 Stinger Systems, Inc. ... today announced,that it had reached a settlement agreement ... Inc. said it settled the matter without admitting ... barring future,violations. Stinger Systems, Inc. also said that ...
Cached Biology News:A new idea for how anti-aging products delay ripening of fruit and wilting of flowers 2A new idea for how anti-aging products delay ripening of fruit and wilting of flowers 3
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... a new technology for sensitive detection ... amounts of DNA (5). This process ... modify the DNA, followed by PCR ... distinguish methylated from unmethylated DNA. The ...
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. iEMS ... a one-cabinet model, allowing the ...
... atlantica Description: Beta-Agarase is useful in ... low-melting-temperature agarose. Beta-Agarase digests the agarose ... Friendly Properties: Heat Inactivation: 65C, 15 ... pH: 6.5 Purity: Tested for contaminating ...
Biology Products: